Cytotoxic T lymphocyte response
Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
9
Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge
8
A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia
12
Comparative Analysis of Cytotoxic T Lymphocyte Response Induced by Dendritic Cells Loaded with Hepatocellular Carcinoma -Derived RNA or Cell Lysate
10
CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection.
7
Acute Resolving Woodchuck Hepatitis Virus (WHV) Infection Is Associated with a Strong Cytotoxic T-Lymphocyte Response to a Single WHV Core Peptide
8
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection
10
In Vivo Induction of a High-Avidity, High-Frequency Cytotoxic T-Lymphocyte Response Is Associated with Antiviral Protective Immunity
7
The cytotoxic T-lymphocyte response to Sendai virus is unimpaired in the absence of gamma interferon.
5
Construction of Hybrid Gene of Hepatitis B Surface Antigen Carrying Heat-Stable Enterotoxin of Escherichia coli and Its Expression in Mammalian Cell Line
7
Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV 1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells
18
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma
12
Cytotoxic T lymphocyte antigen 4 and immune checkpoint blockade
8
Quantitative study of cytotoxic T-lymphocyte immunotherapy for nasopharyngeal carcinoma
12
Human Cytotoxic T-Lymphocyte Repertoire to Influenza A Viruses
8
Feasibility study of personalized peptide vaccination for metastatic recurrent triple negative breast cancer patients
13
Tissue Dimensionality Influences the Functional Response of Cytotoxic T Lymphocyte-Mediated Killing of Targets
12
Dynamics of a fractional order HBV infection model with capsids and CTL immune response
15
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
10
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.
11